Details

Autor(en) / Beteiligte

• Wang, P
• Afriyie-Gyawu, E
• Tang, Y
• Johnson, N.M
• Xu, L
• Tang, L
• Huebner, H.J
• Ankrah, N.A
• Ofori-Adjei, D
• Ellis, W

Titel

NovaSil clay intervention in Ghanaians at high risk for aflatoxicosis: II. Reduction in biomarkers of aflatoxin exposure in blood and urine

Ist Teil von

• Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment, 2008-05, Vol.25 (5), p.622-634

Ort / Verlag

London: Taylor & Francis Group

Erscheinungsjahr

2008

Quelle

Taylor & Francis

Beschreibungen/Notizen

• The efficacy of NovaSil clay (NS) to reduce aflatoxin (AF) biomarkers of exposure was evaluated in 656 blood samples and 624 urine samples collected from study participants during a 3-month phase IIa clinical intervention trial in Ghana. NS was delivered before meals via capsules. Serum AFB1-albumin adduct was measured by radioimmunoassay and urinary AFM1 metabolites were quantified by immunoaffinity-high-performance liquid chromatography (HPLC)-fluorescence methods. Levels of AFB1-albumin adduct in serum samples collected at baseline and at 1 month were similar (p = 0.2354 and p = 0.3645, respectively) among the placebo (PL), low dose (LD, 1.5 g NS day-1), and high dose (HD, 3.0 g NS day-1) groups. However, the levels of AFB1-albumin adduct at 3 months were significantly decreased in both the LD group (p < 0.0001) and the HD group (p < 0.0001) compared with levels in the PL group. Levels of AFM1 in urine samples collected at baseline and at 1 month were not statistically different among the three study groups. However, a significant decrease (up to 58%) in the median level of AFM1 in samples collected at 3 months was found in the HD group when compared with the median level in the PL group (p < 0.0391). In addition, significant effects were found for dose, time, and dose-time interaction with serum AFB1-albumin adduct and dose-time interaction with urinary AFM1 metabolites. The results suggest that capsules containing NS clay can be used to reduce effectively the bioavailability of dietary AF based on a reduction of AF-specific biomarkers.